Hopp til innhold
NHI.no
Annonse
Informasjon, tilstand

Eggstokkreft (NEL)

Kreft i eggstokkene er ofte en diagnose som stilles sent, fordi sykdommen gir få og vage symptomer tidlig i forløpet. I mange tilfeller har sykdommen spredt seg når diagnosen stilles.

Illustrasjonsbilde

Sist oppdatert:

26. okt. 2020

Innhold i artikkelen

Kreft i eggstokkene

Kreft i eggstokkene er den tredje hyppigste form av underlivskreft i Norge (kreft i livmoren  og kreft i livmoren er nummer 1 og 2). Men omtrent seks ganger flere får brystkreft.

Annonse

Eggstokkreft kan stamme fra ulike vevstyper i eggstokken, og det betyr at det finnes flere forskjellige former av eggstokkreft. Omtrent 90 prosent av all kreft i eggstokkene dannes i overflaten av eggstokkene (såkalte epiteliale svulster), mens cirka ti prosent stammer fra det hormonproduserende kjertellaget inne i eggstokkene.

Både dødelighet og antall nye tilfeller har gått litt tilbake det siste tiåret. Sykdommen rammer hyppigst kvinner i 50-60 årene, men kvinner i alle aldre kan få eggstokkreft. Årlig får vel 500 norske kvinner denne diagnosen. Dersom søster eller mor har hatt kreft i eggstokkene, går livstid-risikoen for å utvikle eggstokkreft opp fra cirka to prosent til cirka fem prosent. I gruppen hvor arv spiller en rolle, dukker ofte sykdommen opp i yngre alder enn hos de som utvikler kreft uten at nær familie er rammet.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Ovarialkreft . Referanselisten for dette dokumentet vises nedenfor

  1. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016 Jun 1;93(11):937-944.
  2. Kreftregisteret. Cancer in Norway 2019. Oslo: Kreftregisteret, 2020, www.kreftregisteret.no.
  3. Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clin Obstet Gynecol 2006; 49:464-79. PubMed
  4. Helsedirektoratet. Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft. Eggstokkreft, tubekreft og bukhinnekreft. 2020. helsedirektoratet.no
  5. Michels KA, Pfeiffer RM, Brinton LA, et al. Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers. JAMA Oncol 2018. doi:10.1001/jamaoncol.2017.4942 DOI
  6. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203.
  7. Pruthi S, Gostout BS, Lindor NM. Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer. Mayo Clin Proc. 2010;85(12):1111–1120.
  8. Lyngstadaas A, Ekanger R, Hagen B, et al. Primærbehandling av ovarialcancer. Tidsskr Nor Lægeforen 2005; 125: 278-81. PubMed
  9. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3–23.
  10. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–1333.
  11. Jordan SJ1, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103: 1122-9. pmid:17005245 PubMed
  12. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1·1 million Norwegian women. J Natl Cancer Inst 2003; 95: 1244-48. PubMed
  13. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjær S, Lidegaard Ø. Hormon therapy and ovarian cancer. JAMA 2009; 302: 298-305. Journal of the American Medical Association
  14. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015. doi:10.1016/S0140-6736(14)62458-2 DOI
  15. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188–4198.
  16. Iversen L, Fielding S, Lidegaard Ø, et al. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study BMJ 2018; 362 :k3609. DOI: 10.1136/bmj.k3609. DOI
  17. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer: a Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol 2004; 33: 596-602. PubMed
  18. Kashyap S, Moher D, Fung MF, Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 2004; 103: 785-94. PubMed
  19. Jensen A, Sharif H, Frederiksen K, Kjær SK. Use of fertility drug and risk of ovarian cancer: Danish population based cohort study. BMJ 2009; 338: b249. BMJ (DOI)
  20. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–2303.
  21. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2015;S0140-6736(15):01224-6.
  22. Paulsen T, Kærn J, Kjærheim K, Tropé C, Tretli S. Symptoms and referral of women with epithelial ovarian tumors. Int J Gynaecol Obstet 2005;88(1):31–7. PMID: 15617702. PubMed
  23. Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol 2007; 109: 1053-61. PubMed
  24. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109: 221-7. PubMed
  25. Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009; 339: b2998. BMJ (DOI)
  26. Lindemann K., Solheim O. Om kreft i eggstokk/eggleder. Oncolex 2014
  27. Liu JH, Zanotti KM. Management of the adnexal mass. Obstet Gynecol. 2011;117(6):1413–1428.
  28. Barney SP, Muller CY, Bradshaw KD. Pelvic masses. Med Clin North Am 2008; 92: 1143-61. PubMed
  29. Sevinc A, Adli M, Kalender ME, Camci C. Benign causes of increased serum CA-125 concentration. Lancet Oncol 2007; 8: 1054-5. PubMed
  30. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–2529.
  31. Ameye L, et al. Clinically oriented three-step strategy for assessment of adnexal pathology. Ultrasound Obstet Gynecol. 2012;40(5):582–591.
  32. Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839.
  33. Zhang S, Yu S, Hou W, et al. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors. J Ovarian Res. 2019;12(1):87. Published 2019 Sep 16. PMID: 31526390. PubMed
  34. Lawrie TA, Winter-Roach BA, Heus P, Kitchener HC. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD004706. DOI: 10.1002/14651858.CD004706.pub5 DOI
  35. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.: CD005340. DOI: 10.1002/14651858.CD005340.pub4. The Cochrane Library
  36. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2012; 8: CD005343. DOI: 10.1002/14651858.CD005343.pub3. DOI
  37. Rauh-Hain JA, Melamed A, Wright A. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer. JAMA Oncol 2017; 3(1): 76-82. pmid:27892998 PubMed
  38. Melamed A, Fink G, Wright AA, et al. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ 2018; 360: j5463. doi:10.1136/bmj.j5463 DOI
  39. Fung-Kee-Fung M1, Oliver T, Elit L. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14: 195-208. pmid:17938703 PubMed
  40. Mansoor R. Mirza, M.D., Bradley J et al.. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016. pmid:27717299 PubMed
  41. Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial published correction appears in Lancet Oncol. 2019 May;20(5):e242. Lancet Oncol. 2019;20(5):636-648. PMID: 30948273. PubMed
  42. Mirza MR, Coleman RL, González-Martín A et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020 Jun 19:S0923-7534(20)39891-4. Epub ahead of print. PMID: 32569725. PubMed
  43. Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD001034. DOI: 10.1002/14651858.CD001034.pub2. DOI
  44. Power L, Lefas G, Lambert P, et al. Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival. Obstet Gynecol 2016; 127: 837-47. pmid:27054933 PubMed
  45. Nelson HD, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160(4):255–266.
  46. Henderson JT., Webber EM., Sawaya GF.. Screening for Ovarian Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2017; 319: 595-606. doi:10.1001/jama.2017.21421 DOI
Annonse
Annonse